IDiyas

For the Inventor, By the Inventor

Rodersdorf, Switzerland

Christophe Grundschober

USPTO Granted Patents = 28 

 

 

Average Co-Inventor Count = 4.5

ph-index = 4

Forward Citations = 54(Granted Patents)


Company Filing History:

goldMedal28 out of 4,942 
 
Hoffmann-la Roche Inc.
 patents

Years Active: 2008-2019

Loading Chart...
Loading Chart...
Loading Chart...
28 patents (USPTO):Explore Patents
1. 10265327 - V1A antagonists to treat phase shift sleep disorders (2019-04-23),
2. 9957298 - Peptides as oxytocin agonists (2018-05-01),
3. 9868766 - Peptides as oxytocin agonists (2018-01-16),
4. 9751870 - Oxytocin receptor agonists for the treatment of CNS diseases (2017-09-05),
5. 8580821 - Serotonin transporter (SERT) inhibitors for the treatment of depression and anxiety (2013-11-12),
6. 8202993 - Spiro-piperidine derivatives (2012-06-19),
7. 8143281 - Indoles (2012-03-27),
8. 8084609 - Spiropiperidine derivatives (2011-12-27),
9. 8076360 - Indoles (2011-12-13),
10. 8071622 - Indoles (2011-12-06),
11. 8044202 - Azaspiro derivatives (2011-10-25),
12. 8039624 - Azaspiro derivatives (2011-10-18),
13. 8034937 - Azaspiro derivatives (2011-10-11),
14. 8026259 - Indoles (2011-09-27),
15. 8022213 - Spiro-piperidine derivatives (2011-09-20),

Title: Christophe Grundschober: Innovator in Medical Solutions

Introduction

Christophe Grundschober, based in Rodersdorf, Switzerland, is a distinguished inventor with an impressive portfolio of 28 patents. His work primarily focuses on advancements in medical applications, showcasing innovations that address complex health issues.

Latest Patents

Among his notable inventions, two recent patents stand out. The first is for "V1A antagonists to treat phase shift sleep disorders." This patent introduces a novel medical use for certain chemical compounds and pharmaceutical compositions aimed at treating phase shift sleep disorders, particularly effective against jetlag. The composition includes selective V1A antagonists and a pharmaceutically acceptable carrier.

The second patent relates to "Peptides as oxytocin agonists." This invention encompasses oxytocin receptor agonists intended for the treatment of conditions such as autism, stress disorders, anxiety disorders, depression, and schizophrenia, among others. The compounds aim to provide therapeutic benefits for various psychiatric disorders as well as for conditions like Prader-Willi Syndrome.

Career Highlights

Christophe is currently employed at Hoffmann-La Roche Inc., a renowned company in the pharmaceutical sector. His contributions to the field of medical research and pharmaceutical development have garnered attention and recognition among his peers, solidifying his status as an influential inventor.

Collaborations

Christophe collaborates with several accomplished professionals, including Caterina Bissantz and Patrick Schnider. Together, they pool their expertise and creativity to drive forward innovative solutions in the medical field.

Conclusion

Through his extensive research and dedication to innovation, Christophe Grundschober continues to make a significant impact on the medical community. His patents not only represent his inventiveness but also have the potential to improve the lives of many individuals facing health challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…